Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesNeurology/NeurosurgeryViva Health Onpattro (patisiran) Coverage | OpenPa…
    Ask Trek AI about this page
    CurrentViva HealthPolicy IC-0379

    Onpattro (patisiran) intravenous therapy for hATTR polyneuropathy

    Customize your policy alerts

    Sign up for Viva Health Policy IC-0379 alerts

    Get alerted when Policy IC-0379 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines prior authorization, dosing, approval and renewal criteria, billing codes, and coverage conditions for Onpattro (patisiran) when used to treat polyneuropathy due to hereditary transthyretin-mediated (hATTR) amyloidosis for Viva Health members.

    Policy Summary
    PayerViva Health
    PolicyOnpattro (patisiran) intravenous therapy for hATTR polyneuropathy
    Policy CodePolicy IC-0379
    Change TypeAdministrative review — no material clinical changes
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionObtain prior authorization: initial approval for 6 months (180 days) with renewals every 12 months (365 days) and document baseline strength and definitive hATTR diagnosis.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    18+minimum member age for coverage
    0.3 mg/kg or 30 mgrecommended dosing
    300max units per 3-week dose
    J0222HCPCS code

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Init 6 mo; renew 12 moprior auth validity

    Coverage Criteria for Onpattro (patisiran)

    Initial Therapy

    Covered when ALL of the following are met for initial approval:

    Initial Approval: Member is at least 18 years of age; member is receiving vitamin A supplementation at the recommended daily allowance; must not be used in combination with other transthyretin (TTR) reducing or stabilizing agents (e.g., tafamidis, acoramidis, inotersen, vutrisiran, eplontersen); definitive diagnosis of hATTR amyloidosis documented by suggestive findings (imaging or histopathology) AND identification of a heterozygous pathogenic or likely pathogenic TTR variant by molecular genetic testing; polyneuropathy demonstrated by at least TWO of: subjective symptoms suggestive of neuropathy, abnormal nerve conduction studies consistent with polyneuropathy, or abnormal neurological examination suggestive of neuropathy; peripheral neuropathy attributed to hATTR with other causes of neuropathy excluded; baseline strength documented using an objective clinical measurement tool (e.g., MRC muscle strength); member has not received an orthotopic liver transplant (OLT).all

    Derived from policy section III and Universal Criteria.

    Continuation Therapy

    Renewal permitted when ALL of the following are met:

    Renewal Approval: Member continues to meet the universal and indication-specific criteria from initial approval; absence of unacceptable toxicity from the drug (examples include severe infusion-related reactions and ocular symptoms related to vitamin A deficiency such as night blindness); and disease response versus pre-treatment baseline evidenced by stabilization or improvement in one or more of: signs and symptoms of neuropathy, or MRC muscle strength.all

    From policy section IV.

    Coverage is excluded when the member has received an orthotopic liver transplant (OLT) or when patisiran is administered concomitantly with other transthyretin (TTR) reducing or stabilizing agents. Examples of prohibited concomitant therapies include tafamidis, acoramidis, inotersen, vutrisiran, and eplontersen. Additionally, members must be receiving vitamin A supplementation at the recommended daily allowance as part of universal criteria for use.

    Patisiran (Onpattro) is not covered for indications outside of treatment of polyneuropathy due to hereditary transthyretin-mediated (hATTR) amyloidosis. Coverage in this policy is specific to the polyneuropathy indication and requires documentation consistent with the policy’s diagnostic and clinical criteria.

    Billing and Coding

    HCPCS CodesHCPCSCovered
    J0222Injection, patisiran, 0.1 mg; 1 billable unit = 0.1 mg
    NDCNDCCovered
    71336-1000-xxOnpattro 10 mg/5 mL single-dose vial
    Covered ICD-10 Diagnosis CodesICD-10Covered
    E85.1Neuropathic heredofamilial amyloidosis
    inv-08: Maximum HCPCS units per dosing interval
    Maximum units300 billable HCPCS units per dosing interval (every 3 weeks)
    HCPCS unit definition1 billable unit = 0.1 mg (see HCPCS J0222)
    Dosing intervalEvery 3 weeks (administration schedule tied to max units)

    Provider Requirements, Prior Authorization, and Denial Triggers

    Prior Authorization

    Prior authorization validity and billing/dosing limit

    Prior authorization is required. Initial authorization will be provided for 6 months (180 days); renewals may be approved every 12 months (365 days). Dosing/billing is limited to 300 billable HCPCS units every 3 weeks (1 unit = 0.1 mg, HCPCS J0222).

    • Initial: 6 months (180 days).
    • Renewal: every 12 months (365 days).
    • Dosing limit: 300 billable units per 3 weeks.
    Step Therapy

    Concomitant TTR therapy prohibited

    Onpattro must not be used concomitantly with other transthyretin (TTR) reducing or stabilizing agents.

    • Examples include tafamidis, acoramidis, inotersen, vutrisiran, eplontersen.

    Background

    Hereditary transthyretin-mediated (hATTR) amyloidosis is an inherited disorder in which a heterozygous pathogenic or likely pathogenic variant in the TTR gene leads to deposition of transthyretin amyloid and can cause progressive polyneuropathy. Patisiran (Onpattro) is an RNA interference therapeutic indicated for the treatment of polyneuropathy due to hATTR and is given intravenously. For coverage, the policy requires a definitive diagnosis of hATTR documented in a proband (supporting imaging or histopathology of amyloidosis plus molecular genetic testing identifying a heterozygous pathogenic or likely pathogenic TTR variant). Clinical evidence of polyneuropathy must be demonstrated by at least two findings (subjective neuropathic symptoms, abnormal nerve conduction studies consistent with polyneuropathy, or an abnormal neurological exam), other causes of neuropathy must be excluded, and baseline muscle strength must be documented with an objective tool (for example, Medical Research Council [MRC] muscle strength).

    Definitions

    inv-14: Definitive diagnosis of hATTR amyloidosis
    Definitive diagnostic elementsDocumentation in a proband with suggestive findings (imaging or histopathology consistent with amyloidosis) plus molecular genetic testing identifying a heterozygous pathogenic or likely pathogenic TTR variant.
    Clinical demonstration of polyneuropathyAt least TWO of: subjective symptoms suggestive of neuropathy; abnormal nerve conduction studies consistent with polyneuropathy; or abnormal neurologic exam suggestive of neuropathy.
    Attribution and exclusionPeripheral neuropathy must be attributed to hATTR and other causes of neuropathy excluded.
    Baseline objective measurementBaseline strength/weakness documented using an objective clinical tool (e.g., MRC muscle strength).
    Transplant exclusionMember must not have received an orthotopic liver transplant (OLT).
    Policy Summary
    PayerViva Health
    PolicyOnpattro (patisiran) intravenous therapy for hATTR polyneuropathy
    Policy CodePolicy IC-0379
    Change TypeAdministrative review — no material clinical changes
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionObtain prior authorization: initial approval for 6 months (180 days) with renewals every 12 months (365 days) and document baseline strength and definitive hATTR diagnosis.
    SourceLink
    On This Page
    Coverage Criteria for Onpattro (patisiran)Billing and CodingProvider Requirements, Prior Authorization, and Denial TriggersBackgroundDefinitions
    Documentation Required

    Required clinical documentation for prior authorization

    Providers must supply documentation confirming a definitive diagnosis of hATTR amyloidosis and baseline clinical status prior to authorization.

    • Documentation of definitive hATTR diagnosis: suggestive findings (imaging or histopathology) plus identification of a heterozygous pathogenic or likely pathogenic TTR variant by molecular genetic testing.
    • Evidence polyneuropathy meets criteria: at least two of (subjective neuropathic symptoms; abnormal nerve conduction studies; abnormal neurologic exam).
    • Documentation that peripheral neuropathy is attributed to hATTR with other causes excluded.
    • Baseline objective muscle strength measurement (e.g., MRC).
    • Documentation member is receiving vitamin A supplementation at the recommended daily allowance.
    Denial Risk

    Triggers that may lead to denial

    Cases may be denied if required diagnostic or clinical criteria are not met, if the member has had an orthotopic liver transplant, if Onpattro is used with another TTR-reducing/stabilizing agent, or if unacceptable toxicity is present.

    • Lack of documented definitive hATTR diagnosis with heterozygous pathogenic/likely pathogenic TTR variant.
    • Member has received an orthotopic liver transplant (OLT).
    • Concomitant use with other TTR reducing or stabilizing agents (see examples).
    • Unacceptable toxicity from the drug (e.g., severe infusion-related reactions, ocular symptoms related to vitamin A deficiency such as night blindness).